These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

673 related articles for article (PubMed ID: 29078037)

  • 1. The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies.
    Gumbiner B; Joh T; Liang H; Wan H; Levisetti M; Vana AM; Shelton DL; Forgues P; Billotte S; Pons J; Baum CM; Garzone PD
    Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29078037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin.
    Fazio S; Robertson DG; Joh T; Wan H; Riel T; Forgues P; Baum CM; Garzone PD; Gumbiner B
    Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29057618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia.
    Ballantyne CM; Neutel J; Cropp A; Duggan W; Wang EQ; Plowchalk D; Sweeney K; Kaila N; Vincent J; Bays H
    Am J Cardiol; 2015 May; 115(9):1212-21. PubMed ID: 25784512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.
    Wan H; Gumbiner B; Joh T; Riel T; Udata C; Forgues P; Garzone PD
    Clin Ther; 2017 Nov; 39(11):2243-2259.e5. PubMed ID: 29037448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive　- Results From a Randomized, Placebo-Controlled, Dose-Ranging Study.
    Yokote K; Kanada S; Matsuoka O; Sekino H; Imai K; Tabira J; Matsuoka N; Chaudhuri S; Teramoto T
    Circ J; 2017 Sep; 81(10):1496-1505. PubMed ID: 28539539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of bococizumab, a monoclonal antibody to PCSK9, after single subcutaneous injection at three sites [NCT 02043301].
    Wang EQ; Plotka A; Salageanu J; Sattler C; Yunis C
    Cardiovasc Ther; 2017 Oct; 35(5):. PubMed ID: 28636184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
    McKenney JM; Koren MJ; Kereiakes DJ; Hanotin C; Ferrand AC; Stein EA
    J Am Coll Cardiol; 2012 Jun; 59(25):2344-53. PubMed ID: 22463922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 1 study to evaluate the safety and LDL cholesterol-lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9.
    Baruch A; Luca D; Kahn RS; Cowan KJ; Leabman M; Budha NR; Chiu CPC; Wu Y; Kirchhofer D; Peterson A; Davis JC; Tingley WG
    Clin Cardiol; 2017 Jul; 40(7):503-511. PubMed ID: 28326559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and exploratory efficacy biomarkers of bococizumab, an anti-PCSK9 monoclonal antibody, in hypercholesterolemic Japanese subjects
.
    Yokote K; Suzuki A; Li Y; Matsuoka N; Teramoto T
    Int J Clin Pharmacol Ther; 2019 Dec; 57(12):575-589. PubMed ID: 31549625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for Bococizumab, a Humanized Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, and Its Application in Early Clinical Development.
    Udata C; Garzone PD; Gumbiner B; Joh T; Liang H; Liao KH; Williams JH; Meng X
    J Clin Pharmacol; 2017 Jul; 57(7):855-864. PubMed ID: 28181260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I Randomized Study of a Specifically Engineered, pH-Sensitive PCSK9 Inhibitor RN317 (PF-05335810) in Hypercholesterolemic Subjects on Statin Therapy.
    Levisetti M; Joh T; Wan H; Liang H; Forgues P; Gumbiner B; Garzone PD
    Clin Transl Sci; 2017 Jan; 10(1):3-11. PubMed ID: 27860267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
    Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL;
    J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins.
    Dias CS; Shaywitz AJ; Wasserman SM; Smith BP; Gao B; Stolman DS; Crispino CP; Smirnakis KV; Emery MG; Colbert A; Gibbs JP; Retter MW; Cooke BP; Uy ST; Matson M; Stein EA
    J Am Coll Cardiol; 2012 Nov; 60(19):1888-98. PubMed ID: 23083772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.
    Giugliano RP; Desai NR; Kohli P; Rogers WJ; Somaratne R; Huang F; Liu T; Mohanavelu S; Hoffman EB; McDonald ST; Abrahamsen TE; Wasserman SM; Scott R; Sabatine MS;
    Lancet; 2012 Dec; 380(9858):2007-17. PubMed ID: 23141813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.
    Pradhan AD; Aday AW; Rose LM; Ridker PM
    Circulation; 2018 Jul; 138(2):141-149. PubMed ID: 29716940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study.
    Nam CW; Kim DS; Li J; Baccara-Dinet MT; Li I; Kim JH; Kim CJ
    Korean J Intern Med; 2019 Nov; 34(6):1252-1262. PubMed ID: 30257549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
    Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
    JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
    Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.
    Ridker PM; Revkin J; Amarenco P; Brunell R; Curto M; Civeira F; Flather M; Glynn RJ; Gregoire J; Jukema JW; Karpov Y; Kastelein JJP; Koenig W; Lorenzatti A; Manga P; Masiukiewicz U; Miller M; Mosterd A; Murin J; Nicolau JC; Nissen S; Ponikowski P; Santos RD; Schwartz PF; Soran H; White H; Wright RS; Vrablik M; Yunis C; Shear CL; Tardif JC;
    N Engl J Med; 2017 Apr; 376(16):1527-1539. PubMed ID: 28304242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.
    Stein EA; Mellis S; Yancopoulos GD; Stahl N; Logan D; Smith WB; Lisbon E; Gutierrez M; Webb C; Wu R; Du Y; Kranz T; Gasparino E; Swergold GD
    N Engl J Med; 2012 Mar; 366(12):1108-18. PubMed ID: 22435370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.